Table 2.
Summary of maximal QTcF (Fridericia's correction) postdose and maximal change from baseline in QTcF (per protocol population)
| Treatment | QTcF maximum postdose (ms) |
QTcF maximal change from baseline (ms) |
||||||
|---|---|---|---|---|---|---|---|---|
| ≤450 | >450–480 | >480–500 | >500 | ≤30 | ≥30–60 | ≥60 | ||
| [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | ||
| FF/VI 200/25 μg | 73 (100) | 0 | 0 | 0 | 73 (100) | 0 | 0 | |
| FF/VI 800/100 μg | 73 (100) | 0 | 0 | 0 | 70 (96) | 3 (4) | 0 | |
| Placebo | 73 (100) | 0 | 0 | 0 | 73 (100) | 0 | 0 | |
| Moxifloxacin 400 mg | 69 (95) | 4 (5) | 0 | 0 | 61 (84) | 12 (16) | 0 | |